Learn More
Invitrogen™ BST-2 (CD317) Biosimilar Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody
500.00 € - 1262.00 €
Spezifikation
| Antigen | BST-2 (CD317) Biosimilar |
|---|---|
| Konzentration | 1 mg/mL |
| Inhalt und Lagerung | -20°C, Avoid Freeze/Thaw Cycles |
| Anwendungen | ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance |
| Klassifikation | Recombinant Monoclonal |
| Produktcode | Marke | Menge | Preis | Menge & Verfügbarkeit | |||||
|---|---|---|---|---|---|---|---|---|---|
| Produktcode | Marke | Menge | Preis | Menge & Verfügbarkeit | |||||
30282941
![]() |
Invitrogen™
MA559769 |
100 μg |
500.00 €
100 Mikrogramm |
Log in om dit product te kopen Registreer vandaag om een webaccount aan te maken | |||||
|
30282544
|
Invitrogen™
MA559770 |
1 mg |
1262.00 €
1 Milligramm |
Log in om dit product te kopen Registreer vandaag om een webaccount aan te maken | |||||
Beschreibung
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °. This antibody can also be cross referenced by the term SBI Biotech patent anti-BST2.
BST2 (CD317, HM1.24 antigen, DAMP-2, tetherin) is an integral membrane protein that is involved in the development and growth of B-cells. The surface expression of BST2 on fibroblast cell lines facilitated the stromal cell-dependent growth of DW34, a pre-B-cell line. BST2 is highly expressed during B-cell development, from pro-B precursors to plasma cells, T-cells, monocytes, NK cells and DCs (at protein level), and myeloma cells. Research studies have shown that BST2 also functions as an inhibitor of retrovirus release from human cells whose activity is antagonized by the HIV-1 accessory protein, Vpu. While BST2 causes retention of virions on cell surfaces or endocytosis into BST2-positive compartments, its depletion abolished the viral requirement for Vpu for virus release, an activity that may represent a potential therapeutic strategy for the treatment of HIV/AIDS. Another disease associated with BST2 dysfunction is stomatitis.Spezifikation
| BST-2 (CD317) Biosimilar | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Recombinant Monoclonal | |
| Lyophilized | |
| IgG1 | |
| Human | |
| Primary | |
| Protein A |
| 1 mg/mL | |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| Unconjugated | |
| Human | |
| RUO | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Antibody |
Bitte geben Sie uns Ihr Feedback zu den Produktinhalten, indem Sie das folgende Formular ausfüllen.